CN1095677C - 化合物 - Google Patents

化合物 Download PDF

Info

Publication number
CN1095677C
CN1095677C CN95196986A CN95196986A CN1095677C CN 1095677 C CN1095677 C CN 1095677C CN 95196986 A CN95196986 A CN 95196986A CN 95196986 A CN95196986 A CN 95196986A CN 1095677 C CN1095677 C CN 1095677C
Authority
CN
China
Prior art keywords
dna
enzyme
minutes
cells
prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN95196986A
Other languages
English (en)
Chinese (zh)
Other versions
CN1171054A (zh
Inventor
C·J·泰勒森
H·J·伊格尔提
A·塔拉高纳·菲奥
B·R·拉宾
F·T·博伊尔
J·F·汉南
D·C·布雷基
P·R·马香
D·W·希顿
D·H·戴维斯
A·M·斯拉特
L·F·A·汉纳奎恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
London Biotech Ltd
AstraZeneca UK Ltd
Syngenta Ltd
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1095677(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9426192.2A external-priority patent/GB9426192D0/en
Priority claimed from GBGB9516810.0A external-priority patent/GB9516810D0/en
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of CN1171054A publication Critical patent/CN1171054A/zh
Application granted granted Critical
Publication of CN1095677C publication Critical patent/CN1095677C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Developing Agents For Electrophotography (AREA)
CN95196986A 1994-12-23 1995-12-21 化合物 Expired - Fee Related CN1095677C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9426192.2A GB9426192D0 (en) 1994-12-23 1994-12-23 Chemical compounds
GB9426192.2 1994-12-23
GBGB9516810.0A GB9516810D0 (en) 1995-08-16 1995-08-16 Chemical compounds
GB9516810.0 1995-08-16

Publications (2)

Publication Number Publication Date
CN1171054A CN1171054A (zh) 1998-01-21
CN1095677C true CN1095677C (zh) 2002-12-11

Family

ID=26306259

Family Applications (1)

Application Number Title Priority Date Filing Date
CN95196986A Expired - Fee Related CN1095677C (zh) 1994-12-23 1995-12-21 化合物

Country Status (23)

Country Link
US (1) US5985281A (https=)
EP (1) EP0806964B1 (https=)
JP (1) JP3805365B2 (https=)
KR (1) KR100270650B1 (https=)
CN (1) CN1095677C (https=)
AT (1) ATE222124T1 (https=)
AU (1) AU701916B2 (https=)
BR (1) BR9510490B1 (https=)
CA (1) CA2205091A1 (https=)
CZ (1) CZ195297A3 (https=)
DE (1) DE69527805T2 (https=)
ES (1) ES2181805T3 (https=)
FI (1) FI972683L (https=)
HU (1) HUT77450A (https=)
IL (1) IL116511A0 (https=)
MX (1) MX9704575A (https=)
NO (1) NO972882L (https=)
NZ (1) NZ297529A (https=)
PL (1) PL184031B1 (https=)
RU (1) RU2189251C2 (https=)
SK (1) SK80997A3 (https=)
TR (1) TR199501654A2 (https=)
WO (1) WO1996020011A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1193278A (zh) 1995-08-16 1998-09-16 曾尼卡有限公司 化合物
SG71046A1 (en) 1996-10-10 2000-03-21 Connector Systems Tech Nv High density connector and method of manufacture
AU6000698A (en) * 1997-02-14 1998-09-08 Zeneca Limited Proteins
GB9703201D0 (en) * 1997-02-15 1997-04-02 Zeneca Ltd Chemical compounds
GB9709421D0 (en) * 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
JP4616991B2 (ja) * 1998-09-18 2011-01-19 イミューノメディクス、インコーポレイテッド 化学療法剤の標的特異的な毒性を増加させるための方法および組成物
US6361774B1 (en) 1999-09-17 2002-03-26 Immunomedics, Inc. Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
US20040117863A1 (en) * 1998-09-18 2004-06-17 Edge Michael D. Transgenically produced fusion proteins
EP1220864A4 (en) * 1999-09-17 2003-05-21 Genzyme Transgenics Corp TRANSGENICALLY PRODUCED FUSION PROTEINS
US7067148B2 (en) 2001-02-15 2006-06-27 King Pharmaceutical Research & Development, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
BR0316643A (pt) * 2002-11-27 2005-10-11 Gtc Biotherapeutics Inc Anticorpos modificados estavelmente produzidos no leite e método de produzir os mesmos
US20080019905A9 (en) * 2005-02-18 2008-01-24 Strome Scott E Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
KR20080068089A (ko) * 2005-10-21 2008-07-22 지티씨바이오쎄라퓨틱스,인크. 항체 의존성 세포 독성 활성이 증강된 항체, 그 생산 및사용 방법
US20080031866A1 (en) * 2006-06-20 2008-02-07 Eichenbaum Gary M Method for modulating the pharmacokinetics and metabolism of a therapeutic agent
WO2007149827A2 (en) * 2006-06-20 2007-12-27 Janssen Pharmaceutica, N.V. Method for modulating the pharmacokinetics and metabolism of a therapeutic agent
EP2077991B1 (en) * 2006-10-03 2014-02-26 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of mustards and related compounds with very high skin penetration rates
GB0709333D0 (en) * 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
WO2009134389A2 (en) * 2008-05-01 2009-11-05 Gtc Biotherapeutics, Inc. An anti-cd137 antibody as an agent in the treatment of inflammatory conditions
US10745492B1 (en) * 2019-04-03 2020-08-18 Ark Diagnostics, Inc. Antibodies to symmetrically dimethylated arginine analytes and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995013095A2 (en) * 1993-11-12 1995-05-18 The Wellcome Foundation Limited Therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8705477D0 (en) * 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5632990A (en) * 1988-04-22 1997-05-27 Cancer Research Campaign Tech. Ltd. Treatment for tumors comprising conjugated antibody A5B7 and a prodrug
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
AU648015B2 (en) * 1989-01-23 1994-04-14 Akzo N.V. Site specific in-vivo activation of therapeutic drugs
US5433955A (en) * 1989-01-23 1995-07-18 Akzo N.V. Site specific in vivo activation of therapeutic drugs
AU674137B2 (en) * 1992-01-30 1996-12-12 Genzyme Limited Chiral synthesis with modified enzymes
US5389537A (en) * 1994-01-21 1995-02-14 Wisconsin Alumni Research Foundation Nuclease having altered specificity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995013095A2 (en) * 1993-11-12 1995-05-18 The Wellcome Foundation Limited Therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
《基因》1992,118 1992.1.1 Tarragona-FioL等 *

Also Published As

Publication number Publication date
JP3805365B2 (ja) 2006-08-02
RU2189251C2 (ru) 2002-09-20
IL116511A0 (en) 1996-07-23
HUT77450A (hu) 1998-04-28
CZ195297A3 (en) 1997-12-17
US5985281A (en) 1999-11-16
AU701916B2 (en) 1999-02-11
PL184031B1 (pl) 2002-08-30
JPH10511547A (ja) 1998-11-10
MX9704575A (es) 1997-10-31
NO972882D0 (no) 1997-06-20
FI972683A0 (fi) 1997-06-19
FI972683A7 (fi) 1997-06-19
KR100270650B1 (ko) 2000-11-01
PL320964A1 (en) 1997-11-24
TR199501654A2 (tr) 1996-07-21
NO972882L (no) 1997-08-19
ATE222124T1 (de) 2002-08-15
WO1996020011A1 (en) 1996-07-04
FI972683L (fi) 1997-06-19
BR9510490B1 (pt) 2010-10-05
ES2181805T3 (es) 2003-03-01
CA2205091A1 (en) 1996-07-04
DE69527805D1 (de) 2002-09-19
BR9510490A (pt) 1998-01-13
TR199501654A3 (https=) 1996-07-21
NZ297529A (en) 1999-07-29
EP0806964B1 (en) 2002-08-14
CN1171054A (zh) 1998-01-21
DE69527805T2 (de) 2003-04-24
AU4269796A (en) 1996-07-19
SK80997A3 (en) 1998-02-04
EP0806964A1 (en) 1997-11-19

Similar Documents

Publication Publication Date Title
CN1095677C (zh) 化合物
CN1268743C (zh) 编码细胞靶向部分和异源前体药物活化酶的基因构建体及其应用
HK1042503A1 (zh) 表达以及分泌制管张素和endostatin的免疫融合物
CN1229391C (zh) 涉及α6β4整联蛋白的人胃肠上皮肿瘤抗原的抗体
CN1275085A (zh) 靶细胞的定向细胞溶解、引起细胞溶解的试剂和组合物以及可用于制备这些试剂的化合物
AU688412B2 (en) Therapy
CN1509187A (zh) 细胞毒性cd44抗体免疫偶联物
CN1745103A (zh) 对人IL－1β具有特异性的抗体分子
CN1596313A (zh) 人源化的胶原抗体及相关方法
CN1229498C (zh) 重组的核糖核酸酶蛋白质
CN1606569A (zh) 具有mn结合和细胞粘附中和活性的人类抗体
CN1193278A (zh) 化合物
CN1889937A (zh) 糖基聚乙二醇化的因子ⅸ
CN1897962A (zh) 糖peg化的促红细胞生成素
CN1087642A (zh) 用于释放胞毒剂和其组分的方法
HK1100641A (en) Cab molecules
CN1913913A (zh) Cab分子
HK1064045A (en) Cytotoxic cd44 antibody immunoconjugates
HK1078589A1 (en) Anti-human tenascin monoclonal antibody
HK1078589B (en) Anti-human tenascin monoclonal antibody
HK1056182B (en) Reshaped monoclonal antibodies against an immunoglobulin isotype

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: LONDON BIOLOGYTECHNOLOGY CO., LTD.

Free format text: FORMER OWNER: ASTRAZENECA (UK) LIMITED

Effective date: 20061222

Owner name: SYNGENTA CO., LTD.

Free format text: FORMER OWNER: ZENECA LTD

Effective date: 20061222

Owner name: ASTRAZENECA (UK) LIMITED

Free format text: FORMER OWNER: SYNGENTA CO., LTD.

Effective date: 20061222

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20061222

Address after: London, England

Patentee after: London biotech Ltd.

Address before: London, England

Patentee before: Astrazeneca UK Ltd.

Effective date of registration: 20061222

Address after: London, England

Patentee after: ASTRAZENECA UK LTD.

Address before: surrey

Patentee before: SYNGENTA Ltd.

Effective date of registration: 20061222

Address after: surrey

Patentee after: SYNGENTA Ltd.

Address before: London, England, England

Patentee before: ZENECA Ltd.

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20021211

Termination date: 20100121